Stay updated on SL-401 Combo in AML/MDS/BPDCN Clinical Trial
Sign up to get notified when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.

Latest updates to the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedVersion updated to v3.2.0 with a government funding notice; removal of the term 'CD4+/CD56+ hematodermic neoplasm' from the content.SummaryDifference3%
- Check17 days agoChange DetectedAdded new contact details and updated version to v3.1.0, replacing the previous v3.0.2.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedUpgraded Revision from v3.0.1 to v3.0.2, and removed the Back to Top element. No substantive changes to core content, pricing, stock, or time slots.SummaryDifference0.2%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as detailed information on various hematologic diseases and treatments, including a new clinical trial reference. Some previously listed terms and conditions have been removed.SummaryDifference8%
- Check53 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.9%
Stay in the know with updates to SL-401 Combo in AML/MDS/BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SL-401 Combo in AML/MDS/BPDCN Clinical Trial page.